Literature DB >> 24479135

Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection.

X Wu, M Z Alam, L Feng, L S Tsutsumi, D Sun, J G Hurdle.   

Abstract

AIMS: There is a need for novel treatments for Clostridium difficile infection(CDI). Antibacterial flavonoids are part of a large family of polyphenol phytochemicals with a long history of use in ethnomedicine, but are unexamined against Cl. difficile. We explored their anti-difficile properties. METHODS AND
RESULTS: Anti-difficile activities were determined for several naturally occurring flavonoids, olympicin A and synthetic 4-chromanone and chalcone analogues. With the exception of olympicin A, most naturally occurring phytochemicals tested were poorly active. Diversified synthetic flavonoids resembling olympicin A retained anti-difficile activity, suggesting olympicin A could act as a pharmacophore to obtain novel agents. They also demonstrated concentration-dependent killing of logarithmic and stationary phase cultures and reduced sporulation and toxin production. Olympicin A and some synthetic flavonoids dissipated the bacterial transmembrane potential. Interestingly, mutants could only be selected with the analogue 207 at a frequency of 10(-9).
CONCLUSIONS: Based on the potent anti-difficile properties of olympicin A and modified flavonoids, further exploration of this class of phytochemicals is warranted. SIGNIFICANCE AND IMPACT OF THE STUDY: Clostridium difficile infection is a major problem in developed countries. These studies point to there being an avenue for optimizing plant-derived flavonoids, and related antibacterial phytochemicals, as nature-inspired approaches to treat CDI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24479135      PMCID: PMC3910234          DOI: 10.1111/jam.12344

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  30 in total

1.  Correlation between cytotoxin production and sporulation in Clostridium difficile.

Authors:  S Kamiya; H Ogura; X Q Meng; S Nakamura
Journal:  J Med Microbiol       Date:  1992-09       Impact factor: 2.472

2.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

3.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors:  Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

4.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

5.  Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota.

Authors:  Hui Cheng Lee; Andrew M Jenner; Chin Seng Low; Yuan Kun Lee
Journal:  Res Microbiol       Date:  2006-08-18       Impact factor: 3.992

6.  Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique.

Authors:  D Novo; N G Perlmutter; R H Hunt; H M Shapiro
Journal:  Cytometry       Date:  1999-01-01

Review 7.  Iso- and anteiso-fatty acids in bacteria: biosynthesis, function, and taxonomic significance.

Authors:  T Kaneda
Journal:  Microbiol Rev       Date:  1991-06

Review 8.  Flavonoids, a class of natural products of high pharmacological potency.

Authors:  B Havsteen
Journal:  Biochem Pharmacol       Date:  1983-04-01       Impact factor: 5.858

9.  The membrane as a target for controlling hypervirulent Clostridium difficile infections.

Authors:  Xiaoqian Wu; Philip T Cherian; Richard E Lee; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2012-12-21       Impact factor: 5.790

10.  Emergence and global spread of epidemic healthcare-associated Clostridium difficile.

Authors:  Miao He; Fabio Miyajima; Paul Roberts; Louise Ellison; Derek J Pickard; Melissa J Martin; Thomas R Connor; Simon R Harris; Derek Fairley; Kathleen B Bamford; Stephanie D'Arc; Jon Brazier; Derek Brown; John E Coia; Gill Douce; Dale Gerding; Hee Jung Kim; Tse Hsien Koh; Haru Kato; Mitsutoshi Senoh; Tom Louie; Stephen Michell; Emma Butt; Sharon J Peacock; Nick M Brown; Tom Riley; Glen Songer; Mark Wilcox; Munir Pirmohamed; Ed Kuijper; Peter Hawkey; Brendan W Wren; Gordon Dougan; Julian Parkhill; Trevor D Lawley
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

View more
  14 in total

1.  Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.

Authors:  Mohammed Zahidul Alam; Xiaoqian Wu; Carmela Mascio; Laurent Chesnel; Julian G Hurdle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

2.  Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.

Authors:  Philip T Cherian; Xiaoqian Wu; Lei Yang; Jerrod S Scarborough; Aman P Singh; Zahidul A Alam; Richard E Lee; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2015-08-18       Impact factor: 5.790

3.  Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.

Authors:  Uyen T Dang; Idalia Zamora; Kirk E Hevener; Sudip Adhikari; Xiaoqian Wu; Julian G Hurdle
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  The early stage peptidoglycan biosynthesis Mur enzymes are antibacterial and antisporulation drug targets for recurrent Clostridioides difficile infection.

Authors:  Madhab Sapkota; Ravi K R Marreddy; Xiaoqian Wu; Manish Kumar; Julian G Hurdle
Journal:  Anaerobe       Date:  2019-11-21       Impact factor: 3.331

5.  Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.

Authors:  Li Feng; Marcus M Maddox; Md Zahidul Alam; Lissa S Tsutsumi; Gagandeep Narula; David F Bruhn; Xiaoqian Wu; Shayna Sandhaus; Robin B Lee; Charles J Simmons; Yuk-Ching Tse-Dinh; Julian G Hurdle; Richard E Lee; Dianqing Sun
Journal:  J Med Chem       Date:  2014-10-07       Impact factor: 7.446

6.  Controlling Blown Pack Spoilage Using Anti-Microbial Packaging.

Authors:  Rachael Reid; Declan Bolton; Andrey A Tiuftin; Joe P Kerry; Séamus Fanning; Paul Whyte
Journal:  Foods       Date:  2017-08-12

7.  Blueberry Phenolics Reduce Gastrointestinal Infection of Patients with Cerebral Venous Thrombosis by Improving Depressant-Induced Autoimmune Disorder via miR-155-Mediated Brain-Derived Neurotrophic Factor.

Authors:  Ning Xu; Hao Meng; Tianyi Liu; Yingli Feng; Yuan Qi; Donghuan Zhang; Honglei Wang
Journal:  Front Pharmacol       Date:  2017-11-27       Impact factor: 5.810

Review 8.  Clostridium difficile drug pipeline: challenges in discovery and development of new agents.

Authors:  Angie M Jarrad; Tomislav Karoli; Mark A T Blaskovich; Dena Lyras; Matthew A Cooper
Journal:  J Med Chem       Date:  2015-03-30       Impact factor: 7.446

Review 9.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

10.  Chemical modulation of the biological activity of reutericyclin: a membrane-active antibiotic from Lactobacillus reuteri.

Authors:  Philip T Cherian; Xiaoqian Wu; Marcus M Maddox; Aman P Singh; Richard E Lee; Julian G Hurdle
Journal:  Sci Rep       Date:  2014-04-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.